PLX4720 is a selective inhibitor of BRAF V600E with proven therapeutic efficacy in melanoma models harboring BRAF V600E.[21] We found that P62 was harboring activating BRAF V600E mutations. The gene discussed is BRAF; the disease is melanoma.